Wang Senlan, Tan Jifan, Wang Can, Huang Jia, Zhou Canquan
Reproductive Medicine Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Guangdong Provincial Key Laboratory of Reproductive Medicine, Guangzhou, Guangdong, People's Republic of China.
Int J Womens Health. 2024 Aug 8;16:1349-1359. doi: 10.2147/IJWH.S465541. eCollection 2024.
It is well known that androgen excess impairs oocyte quality, endometrial receptivity and even embryo invasion to some extent. Free androgen index (FAI) is strongly recommended to evaluate active androgen. Previous studies have showed conflicting conclusions on the effect of hyperandrogenism on the pregnancy outcomes in patients with polycystic ovary syndrome (PCOS). This study aims to analyze the influence of hyperandrogenemia based on FAI on frozen embryo transfer (FET) outcomes in patients with PCOS.
Patients diagnosed with PCOS who underwent their first FET between January 2017 and April 2022 were stratified into two cohorts using FAI, a highly recommended parameter: PCOS with hyperandrogenemia (n=73) and PCOS without hyperandrogenemia (n=255). Basic and infertility characteristics were analyzed using Student's -test or chi-square (χ2) statistics. Logistic regression analysis was performed to verify whether FAI was helpful in predicting pregnancy outcomes in women with PCOS.
Body mass index (BMI), total gonadotropin (Gn), basal serum follicle-stimulating hormone (bFSH), basal serum testosterone (bT), sex hormone binding globulin (SHBG), and FAI were significantly different between the two groups. (=0.005, <0.001, <0.001, <0.001, and <0.001, respectively). However, clinical pregnancies, abortions, and live births did not differ significantly. Further regression analyses showed that FAI was not related to clinical pregnancy, abortion, or live birth rates (adjusted odds ratio (OR)=0.978, 95% confidence interval (CI)=0.911-1.050, =0.539; adjusted OR=1.033, 95% CI=0.914-1.168, =0.604; and adjusted OR=0.976, 95% CI=0.911-1.047, =0.499, respectively).
FAI was not associated with pregnancy outcomes in patients with PCOS; that is, it did not reflect any negative effects of hyperandrogenemia on pregnancy outcomes in patients with PCOS and was not an informative clinical parameter. Therefore, more attention should be paid to the factors that influence the accuracy of FAI in reflecting androgen levels in vivo, and further discussion is needed.
众所周知,雄激素过多在一定程度上会损害卵母细胞质量、子宫内膜容受性甚至胚胎着床。强烈推荐使用游离雄激素指数(FAI)来评估活性雄激素。先前的研究对于高雄激素血症对多囊卵巢综合征(PCOS)患者妊娠结局的影响得出了相互矛盾的结论。本研究旨在分析基于FAI的高雄激素血症对PCOS患者冻融胚胎移植(FET)结局的影响。
将2017年1月至2022年4月期间接受首次FET且被诊断为PCOS的患者,根据强烈推荐的参数FAI分为两个队列:高雄激素血症的PCOS患者(n = 73)和无高雄激素血症的PCOS患者(n = 255)。使用Student's -检验或卡方(χ2)统计分析基本特征和不孕特征。进行逻辑回归分析以验证FAI是否有助于预测PCOS女性的妊娠结局。
两组患者的体重指数(BMI)、总促性腺激素(Gn)、基础血清卵泡刺激素(bFSH)、基础血清睾酮(bT)、性激素结合球蛋白(SHBG)和FAI存在显著差异(分别为=0.005,<0.001,<0.001,<0.001和<0.001)。然而,临床妊娠、流产和活产情况并无显著差异。进一步的回归分析表明,FAI与临床妊娠、流产或活产率无关(调整后的优势比(OR)=0.978,95%置信区间(CI)=0.911 - 1.050,=0.539;调整后的OR = 1.033,95% CI = 0.914 - 1.168,=0.604;调整后的OR = 0.976,95% CI = 0.911 - 1.047,=0.499)。
FAI与PCOS患者的妊娠结局无关;也就是说,它未反映高雄激素血症对PCOS患者妊娠结局的任何负面影响,不是一个有参考价值的临床参数。因此,应更多关注影响FAI准确反映体内雄激素水平的因素,尚需进一步探讨。